Cellular Adhesion: Molecular Definition to Therapeutic Potential PDF
Preview Cellular Adhesion: Molecular Definition to Therapeutic Potential
Cellular Adhesion Molecular Definition to Therapeutic Potential NEW HORIZONS IN THERAPEUTICS SmithKline Beecham Pharmaceuticals U.S. Research Symposia Series Series Editors: Brian W. Metcalfand George Poste SmithKline Beecham Pharmaceuticals, Philadelphia, Pennsylvania CELLULAR ADHESION: Molecular Definition to Therapeutic Potential J. Edited by Brian W. Metcalf, Barbara Dalton, and George Poste CELLULAR AND MOLECULAR ASPECTS OF INFLAMMATION Edited by George Poste and Stanley T. Crooke DOPAMINE RECEPTOR AGONISTS Edited by George Poste and Stanley T. Crooke MECHANISMS OF RECEPTOR REGULATION Edited by George Poste and Stanley T. Crooke NEW FRONTIERS IN THE STUDY OF GENE FUNCTIONS Edited by George Poste and Stanley T. Crooke NEW INSIGHTS INTO CELL AND MEMBRANE TRANSPORT PROCESSES Edited by George Poste and Stanley T. Crooke PROTEIN DESIGN AND THE DEVELOPMENT OF NEW THERAPEUTICS AND VACCINES Edited byJerry B. Hook and George Poste Cellular Adhesion Molecular Definition to Therapeutic Potential Edited by BR/AN W. METCALF BARBARA 1. DALTON and GEORGE POSTE SmithKline Beecham Pharmaceuticals Philadelphia, Pennsylvania Technical Editor: JUDY SCHATZ SPRINGER SCIENCE+BUSINESS MEDIA, LLC Library of Congress Cataloging-ln-Publication Data Cellular adhesion : molecular definltion to therapeutlc potenial I edited by Brian W. Metcalf, Barbara J. Dalton, and George Poste. p. cm. -- (New horizons in therapeutics) Includes bibliographical references and index. ISBN 978·1-4613-6050-6 ISBN 978-1-4615-2466-3 (eBook) DOI 10.1007/978-1-4615-2466-3 1. Cell adheSlon molecules--PhySiological effect. 2. Cell adhesion molecules--Therapeutic use. 3. Cell adhesion. 1. Metcalf, Brian W. II. Dalton, Barbara J. III. Poste, George. IV. Series. [DNLM: 1. Cell Adhesion--physiology. 2. Cell Adhesion Molecules -physiology. 3. Integrins--physiology. OH 623 C3936 1994] OP552.C42C46 1994 591.87'6--dc20 DNLM/DLC for Library of Congress 94-27164 CIP ISBN 978-1-4613-6050-6 ©1994 Springer Science+Business Media New York Originally published by Plenum Press in 1994 Softcover reprint of the hardcover Ist edition 1994 AH rights reserved No part of this book may be reproduced. stored in a retrieval system, or transmitted in any form or by allY meallS. electronic, mechanical. photocopying. microfilming, recordillg. or otherwise, without written permission from the Publisher Contributors Omid Abbassi, Department of Pediatrics, Baylor ColJege of Medicine, Houston, Texas 77030 David H. Adams, The Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 Fadia Ali, Department of Medicinal Chemistry, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406 John Bean, Department of Medicinal Chemistry, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406 Donald R. Bertolini, Department of CelJular Biochemistry, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406 James Callahan, Department of Medicinal Chemistry, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406 David A. Cheresh, Department of Immunology, The Scripps Research Institute, La JolJa, California 92037 J. W Costerton, Department of Biological Sciences, University of Calgary, Calgary, Alberta, Canada T2N IN4. Present address: Center for Biofilm Engineering, Montana State University, Bozeman, Montana 59717 Kathryn L. Crossin, Department of Neurobiology, The Scripps Research Institute, La JolJa, California 92037 Mark L. Entman, Section of Cardiovascular Sciences, Department of Medicine, Baylor ColJege of Medicine, Houston, Texas 77030 v VI Contributors David V. Erbe, Department of Immunology, Genentech, Inc., South San Francisco, California 94080 Lynne Flaherty, Department of Surgery, Harborview Medical Center, University of Washington, Seattle, Washington 98104 John M. Harlan, Department of Medicine, Harborview Medical Center, University of Washington, Seattle, Washington 98104 William Huffman, Department of Medicinal Chemistry, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406 David Jones, Department of Chemical Engineering, Rice University, Houston, Texas 77030 Kenneth Kopple, Department of Physical and Structural Chemistry, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406 Paul F. Koster, Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406 Gilbert L. Kukielka, Section of Cardiovascular Sciences, The Methodist Hospital, The DeBakey Heart Center, Department of Medicine, and Speros P. Martel Laboratory of Leukocyte Biology, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas 77030 Laurence A. Lasky, Department of Immunology, Genentech, Inc., South San Francisco, California 94080 D. Euan MacIntyre, Department of Cellular and Molecular Immunology, Merck Research Laboratories, Rahway, New Jersey 07065 Rodger McEver, Department of Medicine and Biochemistry, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104 L. V. McIntire, Department of Chemical Engineering, Rice University, Houston, Texas 77030 Michele Mariscalco, Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030 George E. Mark, III, Department of Cellular and Molecular Biology, Merck Research Laboratories, Rahway, New Jersey 07065 Contributors VII Michael S. Mulligan, Department of Pathology, The University of Michigan, Ann Arbor, Michigan 48109 Andrew J. Nichols, Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406 Eduardo A. Padlan, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892 Catherine PeishojJ, Department of Physical and Structural Chemistry, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406 Leonard G. Presta, Department of Immunology, Genentech, Inc., South San Francisco, California 94080 Anne L. Prieto, Department of Neurobiology, The Scripps Research Institute, La Jolla, California 92037 Martin Ringwald, Max-Planck Institute for Immunobiology, Division of Molecular Embryology, W-7800 Freiburg, Germany. Present address: The Jackson Laboratory, Bar Harbor, Maine 04609 James M. Samanen, Department of Medicinal Chemistry, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406 Stephen Shaw, The Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 Melvin Silberklang, Department of Cellular and Molecular Biology, Merck Research Laboratories, Rahway, New Jersey 07065 Irwin I. Singer, Department of Biochemical and Molecular Pathology, Merck Research Laboratories, Rahway, New Jersey 07065 C. Wayne Smith, Departments of Pediatrics and Microbiology and Immunology, Baylor College of Medicine, Houston, Texas 77030 K. B. Tan, Department of Cellular Biochemistry, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406 Yoshiya Tanaka, The Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 VllI Contributors Richard E. Valocik, Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406 Janice A. Vasko, Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406 Peter A. Ward, Department of Pathology, The University of Michigan, Ann Arbor, Michigan 48109 William I. Weis, Department of Biochemistry and Molecular Biophysics and Howard Hughes Medical Institute, Columbia University, New York, New York 10032. Present address: Department of Cell Biology, Stanford University School of Medicine, Stanford, California 94305 Robert K. Winn, Department of Surgery and Physiology-Biophysics, Harborview Medical Center, University of Washington, Seattle, Washington 98104 Samuel D. Wright, The Laboratory of Cellular Physiology and Immunology, The Rockefeller University, New York, New York 10021 Preface to the Series The unprecedented scope and pace ofdiscovery in modem biology and clinical medicine present remarkable opportunities for the developmentofnew therapeu tic modalities, many of which would have been unimaginable even a few years ago. This situation reflects the unprecedented progress being made not only in disciplines suchas pharmacology, physiology, organicchemistry, andbiochemis try that have traditionally made important contributions to drug discovery, but also in new disciplines such as molecular genetics, gene medicine, cell biology, and immunology that are now ofsufficient maturity to further our understanding ofthe pathogenesis ofdisease and the development ofnovel therapies. Contem porary biomedical research, embracing the entire spectrum ofbiological organi zation from the molecular level to whole body function, is on the thresholdofan era in which biological processes, including disease, can be analyzed in increas ingly precise and mechanistic terms. Thetransformationofbiology from a large ly descriptive, phenomenological discipline to one in which the regulatory prin ciples underlying biological organization can be understood and manipulated with ever-increasing predictability brings an entirely new dimension to the study ofdisease and the search for effective therapeutic modalities. In undergoing this transformation into an increasingly mechanisticdiscipline, biology and medicine are following thecourse already chartedby the sisterdisciplinesofchemistry and physics, albeit still far behind. The consequences of these changes for biomedical research are profound: new concepts; new and increasingly powerful analytical techniques; new ad vancesgeneratedata seeminglyever-rapidpace; an almost unmanageableglutof information dispersed in an increasing number of books and journals; and the task of integrating this information into a realistic experimental framework. Nowhere is the challenge more pronounced than in the pharmaceutical industry. Drug discovery and development have always required the successful coordina tion of multiple scientific disciplines. The need to assimilate more and more disciplines within the drug discovery process, the extraordinary pace of discov ery in all disciplines, and the growing scientific andorganizationalcomplexityof coordinating increasingly ultra-specialized and resource-intensive scientific IX
Description:The list of books you might like
